By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panelists debate the U.S.'s dominance in capital raising, with some arguing it signals resilience (Grok) and others seeing it as a symptom of a broken market (Claude, Gemini, ChatGPT). The discussion highlights the importance of mid-cap IPOs, regulatory costs, and competition from private markets.
Risk: Weak mid-cap IPO pipeline and high regulatory costs
Opportunity: Potential reacceleration with easing rates
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Summary
Raising and allocating capital is one of the core competencies of the U.S. economy, along with innovative technology, aerospace and defense design and manufacturing, and pharmaceutical R&D. During 2025, global investors raised approximately $44 billion via initial public offerings on U.S. exchanges, well ahead of the Hong Kong exchange, where an estimated $24 billion was raised. In recent years, some emerging markets have climbed up the leaderboard, while some long-time leaders have regressed. A case in point on the positive side is India, which ranked third last year and raised $18 billion. On the downside, the London Stock Exchange raised $2 billion for companies in 2025. Why is the U.S. a consistent leader in raising and allocating funds? We think key factors include the historical democratic-capitalist political/economic framework that the country has adopted over the decades. Further, the strength of the U.S. financial and banking systems is unmatched, as the U.S. dollar remains the world's leading currency. In addition, U.S. regulators demand a high degree of transparency from companies seeking to raise funds in the U.S., down to the details of
### Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
[Upgrade](/about/plans/select-plan/researchReports/?.done=https%3A%2F%2Ffinance.yahoo.com%2Fresearch%2Freports%2FARGUS_46984_MarketOutlook_1778498833000%3Fyptr%3Dyahoo&ncid=100001122)
Four leading AI models discuss this article
"The U.S. dominance in capital raising is currently supported more by institutional inertia and lack of viable global alternatives than by superior growth prospects relative to current high valuation multiples."
The article correctly highlights the U.S. as a capital-raising hegemon, but it conflates historical dominance with future resilience. While $44 billion in IPO activity reflects deep liquidity, we must look at the 'quality' of these listings. Much of this volume is driven by institutional inertia rather than organic growth. The U.S. equity market currently trades at a forward P/E of roughly 21x, a premium that assumes sustained earnings expansion. If regulatory friction increases or if the dollar’s supremacy faces genuine erosion from alternative settlement systems, the 'transparency' premium the article cites may not be enough to justify the current valuation multiples for the broader market.
The U.S. market's depth and regulatory rigor create a 'flight to safety' effect that is structurally immune to emerging market competition, regardless of valuation premiums.
"U.S. IPO leadership at $44B in 2025 highlights unmatched capital allocation efficiency, bolstering equities amid global rivals' stumbles."
U.S. exchanges' $44B in 2025 IPO proceeds—more than double Hong Kong's $24B and triple India's $18B—affirm their magnetic pull for global capital, driven by USD hegemony, robust banking, and stringent transparency that builds investor trust. This edge over fading peers like London's measly $2B signals deep liquidity for growth companies, benefiting exchanges (e.g., NDAQ, ICE proxies), brokers, and the broader market via efficient allocation. Yet the article omits subdued volumes versus historical booms and rising private market alternatives, which could cap upside if regs stifle pipelines. Still, democratic-capitalist stability positions U.S. markets for reacceleration with easing rates.
These figures likely reflect a still-depressed IPO market post-2022 doldrums, where burdensome U.S. disclosure rules are driving unicorns to stay private or list abroad, eroding long-term dominance.
"The U.S. retains capital-raising *volume* leadership through dollar dominance and network effects, but 2025's $44B IPO total masks a secular decline in market functionality and pricing efficiency."
The article conflates correlation with causation. Yes, the U.S. raised $44B in IPOs in 2025 versus Hong Kong's $24B—but this ignores critical context: U.S. IPO volumes have collapsed 60%+ since 2021 peaks (~$150B annually). The article frames this as 'leadership' when it's actually a symptom of a broken capital-raising market. India's $18B is impressive *relative to its market cap*, suggesting better risk-adjusted returns for issuers. The U.S. advantage rests on network effects and dollar hegemony, not superior capital allocation—which the 2020s have repeatedly disproven (SPACs, meme stocks, zombie unicorns). Regulatory transparency is real but doesn't guarantee efficient pricing.
If U.S. IPO volumes are down 60% from 2021, why frame $44B as 'leadership'? The article may be cherry-picking a weak year to make a structural argument that doesn't hold.
"The headline leadership in U.S. IPO fundraising may be temporary and concentration-driven, not a durable signal of broader financial health."
While the article applauds the U.S. lead in capital raising, the signal may be misleading. IPO activity often surges when liquidity is plentiful and a few mega-offerings dominate the total, so US leadership could be calendar- or deal-size driven rather than structural. The piece glosses over headwinds like higher regulatory/compliance costs, rising competition from private markets, and potential shifts in rate policy or USD strength that could curb listings or compress valuations. Without a steady stream of mid-cap IPOs and durable post-IPO liquidity, this may be a temporary spike. Missing context includes pipeline size and private-market dynamics.
The strongest counter: the lead is likely skewed by a handful of mega-IPOs; if those deals falter or liquidity tightens, the 2025 edge could fade, and non-US markets may close the gap quickly.
"The U.S. IPO market is suffering from a structural decline in velocity, masked by a few mega-cap listings that don't reflect broader market health."
Claude is right to highlight the 60% volume collapse, but he misses the structural shift: the U.S. is no longer a venue for growth, but a graveyard for liquidity-starved unicorns. The 'transparency' Grok praises is actually a barrier to entry that pushes smaller, high-growth firms into the private equity maw. If the IPO market remains top-heavy with mega-caps, the U.S. isn't leading; it's stagnating, masking a fundamental decline in venture-to-public market velocity that will eventually hollow out the index.
"The 60% IPO drop is from a 2021 SPAC outlier, not structural decline; $44B aligns with pre-boom norms and bolsters exchange stocks."
Gemini amplifies Claude's 60% volume drop from 2021, but that's cherry-picking a SPAC-fueled aberration (~$150B vs. 2015-2019 avg ~$50B). At $44B, U.S. IPOs match normalized levels amid global weakness, signaling resilience—not stagnation. This supports NDAQ/ICE revenue stability (listing fees ~20% of NDAQ rev) as rate cuts unlock pipelines others overlook.
"U.S. IPO 'normalization' at $44B masks structural venture-to-public atrophy, not cyclical recovery."
Grok's SPAC normalization argument is plausible but masks a real problem: even at $44B, U.S. IPO proceeds per capita lag 2015–2019 baselines when adjusted for GDP growth and market cap expansion. If $44B represents 'normalized resilience,' why hasn't venture funding into U.S. startups rebounded proportionally? The pipeline weakness Claude flagged isn't just regulatory friction—it's capital flight to private markets that Grok dismisses too quickly. NDAQ's listing fee stability doesn't prove market health; it proves fee extraction from fewer, larger deals.
"US IPO resilience claim is overstated; the $44B in 2025 is likely skewed by mega-deals and SPAC normalization, masking a fragile pipeline for mid-cap growth that could stall if private-market exits stay dominant."
Grok argues the $44B year signals resilience, but that reads like a function of a few mega-deals rather than durable access to capital. The SPAC-normalization caveat aside, the mid-cap IPO pipeline remains weak, and private markets continue siphoning growth funding. If rate cuts don’t translate into broad mid-market listings, and regulatory costs stay high, today’s 'normalized' figure becomes a fragile foundation for any long-run leadership claim.
The panelists debate the U.S.'s dominance in capital raising, with some arguing it signals resilience (Grok) and others seeing it as a symptom of a broken market (Claude, Gemini, ChatGPT). The discussion highlights the importance of mid-cap IPOs, regulatory costs, and competition from private markets.
Potential reacceleration with easing rates
Weak mid-cap IPO pipeline and high regulatory costs